Stockreport

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study [Yahoo! Finance]

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF - BB-301 facilitated improvements across multiple measures of swallowing function in the first Phase 1b/2a clinical study subject as compared to pretreatment assessment [Read more]